Toshihiko Doi

机构：National Cancer Center Hospital East · ORCID：0000-0003-2042-6829

发表论文 828 篇 · 总被引 30850 次 · h-index 73

代表论文

• Microbiota-driven antitumour immunity mediated by dendritic cell migration (2025 · Nature · 被引 73)
• Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial (2025 · Nature Cancer · 被引 38)
• Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study (2025 · ESMO Open · 被引 15)
• Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial (2026 · The Lancet Oncology · 被引 6)
• Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr) (2025 · Frontiers in Oncology · 被引 5)
• Pimitespib in patients with advanced gastrointestinal stromal tumors in Japan: an expanded access program (2025 · International Journal of Clinical Oncology · 被引 4)